A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 321
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : AA
Long Form : aristolochic acid
No. Year Title Co-occurring Abbreviation
1984 Mutagenicity of the two main components of commercially available carcinogenic aristolochic acid in Salmonella typhimurium. ---
1985 Aristolochic acid induces 6-thioguanine-resistant mutants in an extrahepatic tissue in rats after oral application. MNNG
1985 Aristolochic acid is mutagenic and recombinogenic in Drosophila genotoxicity tests. ---
1987 Acute toxicity of aristolochic acid in rodents. ---
1987 Low oxygen tension, as found in tissues in vivo, alters the mutagenic activity of aristolochic acid I and II in primary fibroblast-like rat cells in vitro. AAI
1988 DNA adduct formation of aristolochic acid I and II in vitro and in vivo. AAI, AAII, CT-DNA
1988 Tumour induction in mice following exposure to aristolochic acid. ---
1990 Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. ---
1990 Effect of butylated hydroxyanisole on the level of DNA adduction by aristolochic acid in the rat forestomach and liver. BHA
10  1993 Effect of diallyl sulfide on aristolochic acid-induced forestomach carcinogenesis in rats. DAS
11  1993 Induction of hepatic nodules in the rat by aristolochic acid. ---
12  1993 Renal toxicity of aristolochic acid in rats as an example of nephrotoxicity testing in routine toxicology. ---
13  1994 Characterization of DNA adducts formed by aristolochic acids in the target organ (forestomach) of rats by 32P-postlabelling analysis using different chromatographic procedures. AAI, AAII
14  1994 Similar patterns of hypomethylation in the beta-hydroxy-beta-methylglutaryl coenzyme A reductase gene in hepatic nodules induced by different carcinogens. 1,2-DMH, HMG CoA
15  1994 Translesional synthesis on DNA templates containing site-specifically placed deoxyadenosine and deoxyguanosine adducts formed by the plant carcinogen aristolochic acid. AAI, AAII
16  1995 Effect of site-specifically located aristolochic acid DNA adducts on in vitro DNA synthesis by human DNA polymerase alpha. ---
17  1996 Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. CHN
18  1997 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. AAII, CHN
19  1997 Comparison of DNA adduct formation by aristolochic acids in various in vitro activation systems by 32P-post-labelling: evidence for reductive activation by peroxidases. AAI, AAII, RAL
20  1997 Involvement of phospholipase A2 in gentamicin-induced rat mesangial cell activation. BN, GENT, PAF, PGE2, PLA2
21  1998 Chinese herbs nephropathy-associated slimming regimen induces tumours in the forestomach but no interstitial nephropathy in rats. CHN, TCC
22  1999 Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy. CHN
23  1999 Urothelial lesions in Chinese-herb nephropathy. CHN, TCC
24  2000 Chinese herb nephropathy in Japan presents adult-onset Fanconi syndrome: could different components of aristolochic acids cause a different type of Chinese herb nephropathy? AAs, CHN
25  2000 Using polymerase arrest to detect DNA binding specificity of aristolochic acid in the mouse H-ras gene. AAI, AAII, dC-AAII
26  2001 Analyses of DNA adducts formed by ochratoxin A and aristolochic acid in patients with Chinese herbs nephropathy. BEN, CHN, OTA
27  2001 Aristolochic acid impedes endocytosis and induces DNA adducts in proximal tubule cells. CHN, LMWP, OK, PT
28  2001 Aristolochic acid nephropathy in a Chinese patient: time to abandon the term "Chinese herbs nephropathy"? AAN, CHN, PAIN
29  2001 Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH : cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy. CHN
30  2001 Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? CHN, ICL, MRs, OCL
31  2001 Evidence for reductive activation of carcinogenic aristolochic acids by prostaglandin H synthase -- (32)P-postlabeling analysis of DNA adduct formation. CHN, PHS, RSV
32  2001 Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. ---
33  2001 Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. AAI, AAII, CHN, TDPCR
34  2001 [Establishment of model of aristolochic acid-induced chronic renal interstitial fibrosis in rats]. beta2-MG, BUN, SCr
35  2001 [The clinical and pathological manifestations of aristolochic acid nephropathy--the report of 58 cases]. AAN, TLC
36  2002 Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. AAI, AAII, AAN
37  2002 Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. CHN
38  2002 Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. XO
39  2002 Mutagenicity of aristolochic acid in the lambda/lacZ transgenic mouse (MutaMouse). CHN, MF, MutaMouse
40  2002 Renal interstitial fibrosis and urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). CHN, ST
41  2002 [Aristolochic acid induced transdifferentiation and apoptosis in human tubular epithelial cells in vitro]. alpha-SMA
42  2002 [The phospholipase A2 inhibitor, aristolochic acid, inhibits chloride secretion without altering barrier function]. PLA2
43  2003 Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date. AAN, BEN, CHN
44  2003 Aristolochic acid nephropathy and the peritoneum: Functional, structural, and molecular studies. AAN, AQP1, bFGF, eNOS
45  2003 Effects of dexfenfluramine on aristolochic acid nephrotoxicity in a rat model for Chinese-herb nephropathy. CHN, DXF, DXF
46  2003 Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. XO
47  2003 The nephrotoxicity of Aristolochia manshuriensis in rats is attributable to its aristolochic acids. AM, AQ, PCNA, TUNEL
48  2003 Transgene-derived hepatocyte growth factor attenuates reactive renal fibrosis in aristolochic acid nephrotoxicity. HGF, TIMP-1
49  2004 Acute nephrotoxicity of aristolochic acids in mice. ALI, CHN, TIN
50  2004 An easy and rapid method to determine aristolochic acids I and II with high sensitivity. CAM, CHN, FA, RA, RST
51  2004 Application of simplified in vitro screening tests to detect genotoxicity of aristolochic acid. ---
52  2004 Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk factor for AA nephropathy-associated cancer. ---
53  2004 DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. AAN
54  2004 Rapid determination of aristolochic acid I and II in Aristolochia plants from different regions by beta-cyclodextrin-modified capillary zone electrophoresis. beta-CD, CHN, CZE, HPLC
55  2004 The renin-angiotensin system blockade does not prevent renal interstitial fibrosis induced by aristolochic acids. AAN, CSN, ENA, RAS
56  2004 [Antagonistic effect of yishen ruanjian san contained serum against aristolochic acid in antagonizing human renal interstitial fibroblasts]. CTGF, ECM, hRIFs, PAI-1, TGF-beta1, TIMP-1
57  2005 An unusual cause of hypokalemic paralysis: aristolochic acid nephropathy with Fanconi syndrome. AAN
58  2005 Detection of Herba Aristolochia Mollissemae in a patient with unexplained nephropathy. ---
59  2005 Early proximal tubule injury in experimental aristolochic acid nephropathy: functional and histological studies. NEP
60  2005 Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. ---
61  2005 Structure activity relationships of aristolochic acid analogues: toxicity in cultured renal epithelial cells. ---
62  2005 The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen. ---
63  2005 [Influence of taking aristolochic acid-containing Chinese drugs on occurrence of urinary transitional cell cancer in uremic uremic patients undergoing dialysis]. NMP, TCC
64  2005 [The medicinal serum of yi-shen ruan-jian san antagonized the effect of aristolochic acid on human proximal tubular epithelial cells in vitro]. CTGF, ECM, LDH, PAI-1, TGF-beta1, TIMP-1
65  2006 Chronic renal failure rats are highly sensitive to aristolochic acids, which are nephrotoxic and carcinogenic agents. CHN, CRF, PCR, RFLP
66  2006 Detection of aristolochic acid I, tetrandrine and fangchinoline in medicinal plants by high performance liquid chromatography and liquid chromatography/mass spectrometry. AAI
67  2006 DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. MF
68  2006 Effect of aristolochic acid on intracellular calcium concentration and its links with apoptosis in renal tubular cells. ---
69  2006 Gene expression profiles distinguish the carcinogenic effects of aristolochic acid in target (kidney) and non-target (liver) tissues in rats. GOFFA
70  2006 Induction of urothelial proliferation in rats by aristolochic acid through cell cycle progression via activation of cyclin D1/cdk4 and cyclin E/cdk2. ---
71  2006 Metabonomic study of aristolochic acid-induced nephrotoxicity in rats. LDA
72  2006 Mutations induced by carcinogenic doses of aristolochic acid in kidney of Big Blue transgenic rats. MFs
73  2006 NMR-based metabonomic study on the subacute toxicity of aristolochic acid in rats. PR
74  2006 Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel electrophoresis analysis. ---
75  2006 Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid by liquid chromatography/tandem mass spectrometry. ---
76  2006 Study on separation of aristolochic acid I and II by micellar electrokinetic capillary chromatography and competition mechanism between SDS and beta-cyclodextrin. ---
77  2006 [Nephropathy caused by Chinese plants and aristolochic acids: from clinical observation to experimental model]. AAN, CHN
78  2006 [Study on transdifferentiation of renal tubular cells in rat chronic renal interstitial fibrosis induced by Radix Aristolochiae Fangchi Extract]. alpha-SMA, CK, RAFE
79  2007 A sensitivity enhanced high-performance liquid chromatography fluorescence method for the detection of nephrotoxic and carcinogenic aristolochic acid in herbal medicines. HPLC-FLD
80  2007 Aristolochic acid and the etiology of endemic (Balkan) nephropathy. AL
81  2007 Aristolochic Acid induces heart failure in zebrafish embryos that is mediated by inflammation. ---
82  2007 Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. AAN, BEN
83  2007 Aristolochic acid-induced cell cycle G1 arrest in human urothelium SV-HUC-1 cells. ---
84  2007 Carcinogen-specific gene expression profiles in short-term treated Eker and wild-type rats indicative of pathways involved in renal tumorigenesis. OTA, TSC2
85  2007 Complexities of the herbal nomenclature system in traditional Chinese medicine (TCM): lessons learned from the misuse of Aristolochia-related species and the importance of the pharmaceutical name during botanical drug product development. TCM
86  2007 Genotoxic effect and nitrative DNA damage in HepG2 cells exposed to aristolochic acid. DAN, MNT, NO, RNS
87  2007 In vitro cytotoxicity assay with selected chemicals using human cells to predict target-organ toxicity of liver and kidney. AAP, MMC, MPT, NR
88  2007 Liquid chromatography-tandem mass spectrometry analysis of the DNA adducts of aristolochic acids. ---
89  2007 Metabolic profiling using combined GC-MS and LC-MS provides a systems understanding of aristolochic acid-induced nephrotoxicity in rat. PCA
90  2007 New molecular and field evidences for the implication of mycotoxins but not aristolochic acid in human nephropathy and urinary tract tumor. BEN, CIT, OTA, UTT
91  2007 Role of mitochondrial permeability transition in human renal tubular epithelial cell death induced by aristolochic acid. AAI, ANT, BA, CsA, MPT
92  2007 Simultaneous determination of nine aristolochic acid analogues in medicinal plants and preparations by high-performance liquid chromatography. HPLC-DAD
93  2008 Aristolochic acid induced changes in the metabolic profile of rat urine. PCA
94  2008 Aristolochic acid nephropathy due to herbal drug intake manifested differently as Fanconi's syndrome and end-stage renal failure--a 7-year follow-up. AAN, ESRF, FS
95  2008 Aristolochic acid nephropathy: a worldwide problem. AAN
96  2008 Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid. ---
97  2008 Characterization of the DNA adducts induced by aristolochic acids in oligonucleotides by electrospray ionization tandem mass spectrometry. ODNs
98  2008 Contribution of biotransformation enzymes to the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions, difficult answers. ---
99  2008 Gene expression profiles modulated by the human carcinogen aristolochic acid I in human cancer cells and their dependence on TP53. AAI
100  2008 Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic aristolochic acid. AAI, AAIa, HPLC
101  2008 Liquid chromatography/mass spectrometry for metabonomics investigation of the biochemical effects induced by aristolochic acid in rats: the use of information-dependent acquisition for biomarker identification. IDA, MS, MS/MS, PCA, PLS-DA
102  2008 Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. BEN
103  2008 Mycotoxic and aristolochic acid theories of the development of endemic nephropathy. EN, OTA
104  2008 Patterns of interstitial inflammation during the evolution of renal injury in experimental aristolochic acid nephropathy. TGF-beta
105  2008 Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003. AA-CHPs, CHPs, NHI
106  2008 Quantification of aristolochic acid-derived DNA adducts in rat kidney and liver by using liquid chromatography-electrospray ionization mass spectrometry. dA-AA, dC-AA, dG-AA, LC-MS
107  2008 Role of phospholipase A2 and tyrosine kinase in Clostridium difficile toxin A-induced disruption of epithelial integrity, histologic inflammatory damage and intestinal secretion. BPB, PLA2, QUIN
108  2008 Species-specific toxicity of aristolochic acid (AA) in vitro. ---
109  2008 Study on the nitric oxide generating effects from aristolochic acid in vitro. AAI, AAII, HIB, NO, RIB
110  2008 [Aristolochic acid induces renal tubular injury and inhibits expression of bone morphogenetic protein-7 mRNA in renal tissue of rats]. AAN, BMP-7, CAM, NAG, PCNA, RT-PCR, SCr, TI
111  2008 [Effects of cytochrome P450 isozymes on aristolochic acid renal cytotoxicity]. ---
112  2008 [Synthesis and mass spectrometric analysis of aristolochic acid-deoxyguanosine adducts]. FT-ICR MS
113  2009 A new approach for the sensitive determination of DNA adduct of aristolochic acid II by using high-performance liquid chromatography with fluorescence detection. dA-AAII, HPLC-FLD
114  2009 beta-Naphthoflavone protects mice from aristolochic acid-I-induced acute kidney injury in a CYP1A dependent mechanism. BNF, i.p
115  2009 Chemical and molecular basis of the carcinogenicity of Aristolochia plants. AAN, BEN
116  2009 Determination of aristolochic acid I and its metabolites in cell culture with a hyphenated high-performance liquid chromatographic technique for cell toxicology. AAI, HPLC-DAD-FLD, LLE
117  2009 Determination of the volatile and semi-volatile secondary metabolites, and aristolochic acids in Aristolochia ringens Vahl. GC, HPLC, HS-SPME, MS, MWHD
118  2009 Fifty years of research in Balkan endemic nephropathy: where are we now? BEN, OTA
119  2009 Improved preparation and identification of aristolochic acid-DNA adducts by solid-phase extraction with liquid chromatography-tandem mass spectrometry. HPLC, LC-DAD-FL, SPE
120  2009 Increased risks of chronic kidney disease associated with prescribed Chinese herbal products suspected to contain aristolochic acid. CHP, CKD, ESRD
121  2009 Molecular evidence for an involvement of organic anion transporters (OATs) in aristolochic acid nephropathy. AAI, OATs
122  2009 Ochratoxin A and aristolochic acid involvement in nephropathies and associated urothelial tract tumours. AAN, BEN, OTA
123  2009 p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy. ---
124  2009 Simple and rapid analysis of aristolochic acid contained in crude drugs and Kampo formulations with solid-phase extraction and HPLC photodiode-array detection. ---
125  2009 TGF-beta 1/Smads signaling stimulates renal interstitial fibrosis in experimental AAN. AAI, AAN, alpha-SMA, CK18, PBS, RT-PCR, TGF-beta1
126  2009 The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers. AAI, AAIa, AAN, BEN
127  2009 TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. BEN
128  2009 [Aristolochic acid nephropathy]. ---
129  2010 Activation of p53 promotes renal injury in acute aristolochic acid nephropathy. AAN, TECs
130  2010 Aristolochic acid suppresses DNA repair and triggers oxidative DNA damage in human kidney proximal tubular cells. AAN, qRT-PCR
131  2010 Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. AAN
132  2010 Herbal medicines and chronic kidney disease. CKD
133  2010 Is Duhuo Jisheng Tang containing Xixin safe? A four-week safety study. ADRs, AEs, DJT, GC-MS, OA, TLC
134  2010 Liquid chromatography/mass spectrometry for investigating the biochemical effects induced by aristolochic acid in rats: the plasma metabolome. ---
135  2010 Low-dose darbepoetin alpha attenuates progression of a mouse model of aristolochic acid nephropathy through early tubular protection. DPO
136  2010 Mechanism of chronic aristolochic acid nephropathy: role of Smad3. AAN, EMT, TGF, WT/KO
137  2010 Microarray analysis reveals the inhibition of nuclear factor-kappa B signaling by aristolochic acid in normal human kidney (HK-2) cells. NF-kappaB, qRT-PCR
138  2010 Protective effect of BMP-7 against aristolochic acid-induced renal tubular epithelial cell injury. AAN, alpha-SMA, BMP-7, EMT, LDH
139  2010 Suspects in etiology of endemic nephropathy: aristolochic acid versus mycotoxins. CHN, EN, UTT
140  2010 Therapeutic remedies based on Aristolochia clematitis in the main foci of Balkan endemic nephropathy in Romania. BEN
141  2011 Aristolochic acid downregulates monocytic matrix metalloproteinase-9 by inhibiting nuclear factor-kappaB activation. ECM, MMP, TIMP, TNF
142  2011 Aristolochic acid induces apoptosis of human umbilical vein endothelial cells in vitro by suppressing PI3K/Akt signaling pathway. HUVECs
143  2011 Aristolochic acid-induced carcinogenesis examined by ACB-PCR quantification of H-Ras and K-Ras mutant fraction. ACB-PCR, BW, MF
144  2011 Aristolochic acid-induced destruction of organic ion transporters and fatty acid metabolic disorder in the kidney of rats. AAN, BUN, LCFAs, NEFA, TG
145  2011 Association between urothelial carcinoma after kidney transplantation and aristolochic acid exposure: the potential role of aristolochic acid in HRas and TP53 gene mutations. UC
146  2011 Comparative nephrotoxicity of aristolochic acid and tetrandrine in vitro and in vivo. DAPI, MDCK, Tet
147  2011 Comparing next-generation sequencing and microarray technologies in a toxicological study of the effects of aristolochic acid on rat kidneys. DEGs
148  2011 Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases. AAI, NATs, SULTs
149  2011 Critical role of organic anion transporters 1 and 3 in kidney accumulation and toxicity of aristolochic acid I. AAI, AAN, OATs
150  2011 Ergosta-4,6,8(14),22-tetraen-3-one isolated from Polyporus umbellatus prevents early renal injury in aristolochic acid-induced nephropathy rats. AAI, NAG
151  2011 Gene expression changes induced by the human carcinogen aristolochic acid I in renal and hepatic tissue of mice. AAI, qRT-PCR
152  2011 Genetic loci that affect aristolochic acid-induced nephrotoxicity in the mouse. AAN, BEN, QTL
153  2011 Glutamate dehydrogenase requirement for apoptosis induced by aristolochic acid in renal tubular epithelial cells. ATP, GDH, TEC
154  2011 High doses of TGF-beta potently suppress type I collagen via the transcription factor CUX1. TGF-beta
155  2011 Physiological and molecular characterization of aristolochic acid transport by the kidney. ---
156  2011 Proteomics investigation on aristolochic acid nephropathy: a case study on rat kidney tissues. ---
157  2011 Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity. hL-FABP, L-FABP, Tg, Tg-AA, TID, WT
158  2011 Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. AAI, WT
159  2011 Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver. AAIa, AAN, BEN
160  2011 The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. AAI, NATs, SULTs
161  2011 The molecular mechanism of leptin secretion and expression induced by aristolochic acid in kidney fibroblast. ---
162  2011 TP53 Mutational signature for aristolochic acid: an environmental carcinogen. UUC
163  2012 ACB-PCR measurement of H-ras codon 61 CAA→CTA mutation provides an early indication of aristolochic acid I carcinogenic effect in tumor target tissues. ACB-PCR, MF
164  2012 Altered tight junctions and fence function in NRK-52E cells induced by aristolochic acid. REC, TEER, TJs, ZO-1
165  2012 Aristolochia manshuriensis Kom inhibits adipocyte differentiation by regulation of ERK1/2 and Akt pathway. AMK, FAS, HFD, LDL-C, LPL, MEK1, PDK1, PPARgamma, TC
166  2012 Aristolochic acid I induced autophagy extenuates cell apoptosis via ERK 1/2 pathway in renal tubular epithelial cells. JNK
167  2012 Aristolochic acid nephropathy: variation in presentation and prognosis. AAN, CKD, eGFR, SCr
168  2012 Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. ---
169  2012 Chinese herbs nephropathy and Balkan endemic nephropathy: toward a single entity, aristolochic acid nephropathy. BEN, CHN
170  2012 Clinical and pathological spectrums of aristolochic acid nephropathy. AAN, AKI, ESRD, NAG, RBP, TBM
171  2012 Comparison of the mutagenicity of aristolochic acid I and aristolochic acid II in the gpt delta transgenic mouse kidney. AAI, AAII
172  2012 Developmental nephrotoxicity of aristolochic acid in a zebrafish model. GFRs
173  2012 Endoplasmic reticulum stress mediates aristolochic acid I-induced apoptosis in human renal proximal tubular epithelial cells. 4-PBA, AAI, AAN, CHOP, eIF2alpha, ER, GRP, NAC, ROS, Sal, XBP1
174  2012 Evidence of exposure to aristolochic acid in patients with urothelial cancer from a Balkan endemic nephropathy region of Romania. BEN, UUC
175  2012 Gremlin-mediated decrease in bone morphogenetic protein signaling promotes aristolochic acid-induced epithelial-to-mesenchymal transition (EMT) in HK-2 cells. AAN, alpha-SMA, BMP-7, EMT, PTEC
176  2012 Hemizygous deletion of CTGF/CCN2 does not suffice to prevent fibrosis of the severely injured kidney. UUO
177  2012 Isogenic mesenchymal stem cells transplantation improves a rat model of chronic aristolochic acid nephropathy via upregulation of hepatic growth factor and downregulation of transforming growth factor beta1. BM, HGF, MSCs
178  2012 JNK-dependent AP-1 activation is required for aristolochic acid-induced TGF-beta1 synthesis in human renal proximal epithelial cells. CAAN, TGF-beta1
179  2012 Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. AL, GG-NER
180  2012 Mutagenicity and DNA adduct formation by aristolochic acid in the spleen of Big Blue rats. ---
181  2012 Not all sugars are created equal: some mask aversive tastes better than others in an herbivorous insect. CAF, GLU, Ino, Suc
182  2012 Proteome alterations in response to aristolochic acids in experimental animal model. EN, UUTC
183  2012 The safety of Homnawakod herbal formula containing Aristolochia tagala Cham. in Wistar rats. HNK, LPS, MAP
184  2012 Theoretical investigation of differences in nitroreduction of aristolochic acid I by cytochromes P450 1A1, 1A2 and 1B1. AAN, BEN
185  2013 A novel p53 mutant found in iatrogenic urothelial cancers is dysfunctional and can be rescued by a second-site global suppressor mutation. ---
186  2013 Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. UUT
187  2013 Aristolochic acid causes albuminuria by promoting mitochondrial DNA damage and dysfunction in podocyte. mtDNA
188  2013 Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. ---
189  2013 Association between aristolochic acid and CKD: a cross-sectional survey in China. CKD, eGFR
190  2013 Autophagy induction promotes aristolochic acid-I-induced renal injury in vivo and in vitro. ---
191  2013 Development of a Medium-term Animal Model Using gpt Delta Rats to Evaluate Chemical Carcinogenicity and Genotoxicity. 2-AAF, DEN, GST-P, i.p, MFs, PBO, PH, PHE, SF
192  2013 Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer. AAI, AAIa, AAN, BEN, CYP1A2
193  2013 Genome-wide mutational signatures of aristolochic acid and its application as a screening tool. UTUC
194  2013 Gustatory receptor neurons in Manduca sexta contain a TrpA1-dependent signaling pathway that integrates taste and temperature. TRP
195  2013 Metabolomic analysis of complex chinese remedies: examples of induced nephrotoxicity in the mouse from a series of remedies containing aristolochic Acid. BFAJT
196  2013 Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. ---
197  2013 Novel assays for detection of urinary KIM-1 in mouse models of kidney injury. KIM-1, NAG, SCr, uKIM-1
198  2013 The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. AAN
199  2013 Variation in presentation and presence of DNA adducts and p53 mutations in patients with endemic nephropathy--an environmental form of the aristolochic acid nephropathy. AL, EN
200  2013 Zebrafish heart failure models for the evaluation of chemical probes and drugs. MEK-I
201  2014 Acute kidney injury induced by aristolochic acid in patients with primary glomerular nephritis. AAN, CGN, SCr
202  2014 An exploratory evaluation of the utility of transcriptional and urinary kidney injury biomarkers for the prediction of aristolochic acid-induced renal injury in male rats. ---
203  2014 Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway. AAI, AAN, AKI, BARD, BUN, HO-1, i.p, Keap1, NQO1, Nrf2, SCr
204  2014 Chinese herbs containing aristolochic acid associated with renal failure and urothelial carcinoma: a review from epidemiologic observations to causal inference. ---
205  2014 Downregulation of connective tissue growth factor by LPS/IFN-gamma-induced nitric oxide is reversed by aristolochic acid treatment in glomerular mesangial cells via STAT-1alpha and NF-kappaB signaling. AAN, CTGF, IFN-gamma, iNOS, IRF-1, LPS, NO, NOS, STAT-1alpha
206  2014 Effect of Sedum sarmentosum BUNGE extract on aristolochic acid-induced renal tubular epithelial cell injury. EMT, SSB
207  2014 Evaluating weight of evidence in the mystery of Balkan endemic nephropathy. BEN, BHC, OTA
208  2014 Exceptionally long-term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy. AAN, BEN, dA-AAI
209  2014 Formalin-fixed paraffin-embedded tissue as a source for quantitation of carcinogen DNA adducts: aristolochic acid as a prototype carcinogen. FFPE
210  2014 Improvement and validation of a medium-term gpt delta rat model for predicting chemical carcinogenicity and underlying mode of action. DEN, ES
211  2014 Increased renal semicarbazide-sensitive amine oxidase activity and methylglyoxal levels in aristolochic acid-induced nephrotoxicity. MGO, SSAO
212  2014 Increased risk of urinary tract cancer in ESRD patients associated with usage of Chinese herbal products suspected of containing aristolochic acid. ESRD, UC
213  2014 Interaction of phospholipase A of the E. coli outer membrane with the inhibitors of eucaryotic phospholipases A₂ and their effect on the Ca⁺-induced permeabilization of the bacterial membrane. ---
214  2014 Non-aristolochic acid prescribed Chinese herbal medicines and the risk of mortality in patients with chronic kidney disease: results from a population-based follow-up study. aHR, CHMs, CKD
215  2014 Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center. UTUC
216  2014 Sedum sarmentosum Bunge extract exerts renal anti-fibrotic effects in vivo and in vitro. ECM, EMT, RTECs, SSBE, UUO
217  2014 Tissue-specific microRNA responses in rats treated with mutagenic and carcinogenic doses of aristolochic acid. miRNA
218  2014 Variation in genomic landscape of clear cell renal cell carcinoma across Europe. ccRCC, ECM, RCC
219  2014 [Advance in studies on toxicity of aristolochic acid and analysis on risk factors]. ---
220  2015 Analysis of potential risk factors for cancer incidence in patients with aristolochic acid nephropathy from Wenzhou, China. AAN, CYP1A1, ESRD
221  2015 Aristolochic acid nephropathy: epidemiology, clinical presentation, and treatment. AAN, ESRD
222  2015 Comparison of DNA and RNA Adduct Formation: Significantly Higher Levels of RNA than DNA Modifications in the Internal Organs of Aristolochic Acid-Dosed Rats. ---
223  2015 Differential microRNA expression in aristolochic acid-induced upper urothelial tract cancers ex vivo. CKD, UUC
224  2015 Human bone morphogenetic protein-7 does not counteract aristolochic acid-induced renal toxicity. rhBMP
225  2015 Impairment of the Cellular Distribution and Stability of the Erythropoietin Receptor Through the Direct Targeting of Aristolochic Acid. EpoR
226  2015 Integrated microRNA, mRNA, and protein expression profiling reveals microRNA regulatory networks in rat kidney treated with a carcinogenic dose of aristolochic acid. HCA, IPA, miRNAs, PCA
227  2015 Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid. LC-WES
228  2015 Mass Spectrometric and Spectrofluorometric Studies of the Interaction of Aristolochic Acids with Proteins. AAI, AAII, BSA, MS
229  2015 Mutation signatures implicate aristolochic acid in bladder cancer development. ---
230  2015 Nephroprotective role of resveratrol and ursolic Acid in aristolochic Acid intoxicated zebrafish. RESV, UA
231  2015 New Approaches for Biomonitoring Exposure to the Human Carcinogen Aristolochic Acid. AAN, AL, FFPE
232  2015 Prediction and Characterisation of the System Effects of Aristolochic Acid: A Novel Joint Network Analysis towards Therapeutic and Toxicological Mechanisms. PPI
233  2015 Quantification of aristolochic acid-RNA adducts in the urine of aristolochic acid-treated rats by liquid chromatography-tandem mass spectrometry. BEN
234  2015 Reduced kidney levels of lysophosphatidic acids in rats after chronic administration of aristolochic acid: Its possible protective role in renal fibrosis. LPA
235  2015 Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid. AAN, EN, RCC
236  2015 Revealing a Pre-neoplastic Renal Tubular Lesion by p-S6 Protein Immunohistochemistry after Rat Exposure to Aristolochic Acid. ---
237  2015 Substitution between Aristolochia and Bryonia genus in North-Eastern Morocco: toxicological implications. ---
238  2015 The genome as a record of environmental exposure. BaP, UV
239  2015 The influence of ochratoxin A on DNA adduct formation by the carcinogen aristolochic acid in rats. BEN, OTA, UUC
240  2015 Understanding the aristolochic acid toxicities in rat kidneys with regulatory networks. ---
241  2015 Upper urinary tract disease: what we know today and unmet needs. AC, RNU, UCB, UTUC
242  2015 Urinary metabolomics and biomarkers of aristolochic acid nephrotoxicity by UPLC-QTOF/HDMS. ---
243  2015 Vitamin C attenuates the toxic effect of aristolochic acid on renal tubular cells via decreasing oxidative stress‑mediated cell death pathways. ---
244  2015 [Application of ultra high performance liquid chromatography-mass spectrometry to metabolomics study of drug-induced hepatotoxicity]. UPLC-MS
245  2015 [Exploring the Correlation between Pi and Shen from the Excretion of AA-I and Expressions of Or- ganic Anion Transporting Polypeptide 2al and 2 b1 in Pi Deficiency Model Rats]. OATP, PDS, RT- PCR, SD
246  2016 Application of small RNA sequencing to identify microRNAs in acute kidney injury and fibrosis. miRNA
247  2016 Aristolochic acid exposure in Romania and implications for renal cell carcinoma. AAN, AL, RCC, UUTC
248  2016 Aristolochic Acid I Causes Testis Toxicity by Inhibiting Akt and ERK1/2 Phosphorylation. AAI, Bcl-2
249  2016 Aristolochic Acid in the Etiology of Renal Cell Carcinoma. AL, ccRCC
250  2016 Balkan endemic nephropathy: an update on its aetiology. BEN, UUC
251  2016 Evaluation for a mutagenicity of aristolochic acid by Pig-a and PIGRET assays in rats. IWGT, PIG-A
252  2016 Evaluation of nephrotoxic effects of aristolochic acid on zebrafish (Danio rerio) larvae. ---
253  2016 Expression of Renal Aquaporins in Aristolochic Acid I and Aristolactam I-Induced Nephrotoxicity. AL-I, AQPs
254  2016 Hirsutella sinensis Attenuates Aristolochic Acid-Induced Renal Tubular Epithelial-Mesenchymal Transition by Inhibiting TGF-beta1 and Snail Expression. alpha-SMA, Ccr, EMT, HS, TGF-beta1
255  2016 Inhibition of Macrophage Migration Inhibitory Factor Protects against Inflammation and Matrix Deposition in Kidney Tissues after Injury. MIF, TECs
256  2016 Interplay between chronic kidney disease (CKD) and upper tract urothelial carcinomas (UUC): foe or friend? CKD
257  2016 Long-term Outcome of Kidney Recipients Transplanted for Aristolochic Acid Nephropathy. AAN
258  2016 Lynch syndrome and exposure to aristolochic acid in upper-tract urothelial carcinoma: its clinical impact? BNe, HNPCC, LS, UTUC
259  2016 New in vitro insights on a cell death pathway induced by magnolol and honokiol in aristolochic acid tubulotoxicity. ---
260  2016 Omeprazole Alleviates Aristolochia manshuriensis Kom-Induced Acute Nephrotoxicity. AMK, OM
261  2016 Patients with urothelial carcinoma have poor renal outcome regardless of whether they receive nephrouretectomy. BUC, CI, HRs, UC, UTUC
262  2016 Preparation of a nitric oxide imaging agent from gelatin derivative micelles. LPS, NO
263  2016 Protective effect of nitric oxide in aristolochic acid-induced toxic acute kidney injury: an old friend with new assets. L-Arg, NO, NOX2
264  2016 Reduced rat plasma lysophosphatidylglycerol or lysophosphatidic acid level as a biomarker of aristolochic acid-induced renal and adipose dysfunctions. LPA, LPG, LPL
265  2016 Sulfotransferase-1A1-dependent bioactivation of aristolochic acid I and N-hydroxyaristolactam I in human cells. AL-I-NOH, SULT
266  2016 Transforming growth factor-beta1 stimulates hedgehog signaling to promote epithelial-mesenchymal transition after kidney injury. ECM, EMT, TECs, TGF
267  2017 A systematic review of the possible carcinogenic role of the aristolochic acid. UTUC
268  2017 An Integrated View of Aristolochic Acid Nephropathy: Update of the Literature. AAN
269  2017 Aristolochic acid and its derivatives as inhibitors of snake venom L-amino acid oxidase. LAAO, ROS
270  2017 Aristolochic Acid-Induced Autophagy Promotes Epithelial-to-Myofibroblast Transition in Human Renal Proximal Tubule Epithelial Cells. EMT
271  2017 DNA Adducts Formed by Aristolochic Acid Are Unique Biomarkers of Exposure and Explain the Initiation Phase of Upper Urothelial Cancer. AAI, AAN, BEN, UUC
272  2017 Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial? SGLT2
273  2017 Impact of aristolochic acid exposure on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. HR, IVR, RNU, UTUC
274  2017 Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzanthrone. 3-NBA, AAI, AAII, AAN, BEN, SULT1A1, WT
275  2017 Prescribed Renoprotective Chinese Herbal Medicines Were Associated with a Lower Risk of All-Cause and Disease-Specific Mortality among Patients with Chronic Kidney Disease: A Population-Based Follow-Up Study in Taiwan. aHR, CHMs, CKD, RPCHM
276  2017 Protective effects of cyclic helix B peptide on aristolochic acid induced acute kidney injury. CHBP
277  2017 Restored nitric oxide bioavailability reduces the severity of acute-to-chronic transition in a mouse model of aristolochic acid nephropathy. AKI, CKD, L-Arg, NO
278  2017 The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-beta1. AAN, BZM, CKD, MM
279  2017 TP53 mutations in p53-negative dysplastic urothelial cells from Belgian AAN patients: New evidence for aristolochic acid-induced molecular pathogenesis and carcinogenesis. AAN, IHC, UC
280  2017 Urinary Time- or Dose-Dependent Metabolic Biomarkers of Aristolochic Acid-Induced Nephrotoxicity in Rats. BUN, GC-MS
281  2018 A comparison between the effects of ochratoxin A and aristolochic acid on the inflammation and oxidative stress in the liver and kidney of weanling piglets. CAT, GPx, IFN, IL, OTA, SOD, TNF
282  2018 Aristolochic acid containing herbs induce gender-related oncological differences in upper tract urothelial carcinoma patients. BR, CSS, CUTR, UTUC
283  2018 Carcinogens that induce the A:T > T:A nucleotide substitutions in the genome. HCC
284  2018 Cooking methods employing natural anti-oxidant food additives effectively reduced concentration of nephrotoxic and carcinogenic aristolochic acids in contaminated food grains. ---
285  2018 Deregulation of Hippo-TAZ pathway during renal injury confers a fibrotic maladaptive phenotype. CKD, CTGF, HK, Smad, TAZ, YAP
286  2018 Effect of phospholipase A2 inhibitors during infection caused by Leishmania (Leishmania) amazonensis. BEL, MAFP, PLA2
287  2018 Glucofucogalactan, a heterogeneous low-sulfated polysaccharide from Saccharina japonica and its bioactivity. ---
288  2018 Glycine N-methyltransferase inhibits aristolochic acid nephropathy by increasing CYP3A44 and decreasing NQO1 expression in female mouse hepatocytes. AAI, GNMT
289  2018 Human Liver Stem Cell-Derived Extracellular Vesicles Prevent Aristolochic Acid-Induced Kidney Fibrosis. CKD, HLSC-EVs, miRNAs
290  2018 Inhibition of phospholipases influences the metabolism of wound-induced benzylisoquinoline alkaloids in Papaver somniferum L. BIAs, FIPI, PLD
291  2018 Proteomics analysis of altered proteins in kidney of mice with aristolochic acid nephropathy using the fluorogenic derivatization-liquid chromatography-tandem mass spectrometry method. AAN, GPR87, TSP1
292  2018 Update of aristolochic acid nephropathy in Korea. AAN, ESRD
293  2018 Vitamin E (alpha‑tocopherol) ameliorates aristolochic acid‑induced renal tubular epithelial cell death by attenuating oxidative stress and caspase‑3 activation. ---
294  2019 Aristolochic Acid Affects Upper Tract Urothelial Cancer Behavior through the MAPK Pathway. ERK, MAPK, MCA, UTUC
295  2019 Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs. UCB
296  2019 Assessment of nephrotoxicity of herbal medicine containing aristolochic acid in mice. HM, NGAL, TUNEL
297  2019 Balkan Endemic Nephropathy and the Causative Role of Aristolochic Acid. ---
298  2019 Bardoxolone ameliorates TGF-beta1-associated renal fibrosis through Nrf2/Smad7 elevation. alpha-SMA, BARD, ECM, Keap1, Smurf1, TbetaR1, TGF-beta
299  2019 Comparison of Aristolochic acid I derived DNA adduct levels in human renal toxicity models. AAI, pHKC
300  2019 Developed a novel sensor based on fluorescent graft conjugated polymer for the determination of aristolochic acid in traditional Chinese medicine. LOD
301  2019 Effects of Human Placental Amnion Derived Mesenchymal Stem Cells on Proliferation and Apoptosis Mechanisms in Chronic Kidney Disease in the Rat. CKF, hAMSCs, MSCs
302  2019 Electromembrane extraction of aristolochic acids: New insights in separation of bioactive ingredients of traditional Chinese medicines. ALA, EME, RA, TCMs
303  2019 Exposure to aristolochic acid I compromises the maturational competency of porcine oocytes via oxidative stress-induced DNA damage. ---
304  2019 Genome-wide somatic mutation analysis via Hawk-Seq™ reveals mutation profiles associated with chemical mutagens. BP, DEN, ENU, MNU
305  2019 Herbal Medicine Containing Aristolochic Acid and the Risk of Primary Liver Cancer in Patients with Hepatitis C Virus Infection. CI, HCV, HM, PLC
306  2019 Inhibition of 4E-BP1 phosphorylation promotes tubular cell escaping from G2/M arrest and ameliorates kidney fibrosis. ---
307  2019 Mitochondrial dysfunction is involved in aristolochic acid I-induced apoptosis in renal proximaltubular epithelialcells. AAI, AAN, ATP, MMP, mtDNA, NRK-52E, PTEC, ROS
308  2019 Prevalence, clinicopathological features, and prognosis in upper tract urinary carcinoma patients with severe preoperative chronic kidney disease. CKD, CSS, eGFR, IVR, MDRD, OS, RNU, UTUC
309  2019 Protective Effects of Melatonin Against Aristolochic Acid-Induced Nephropathy in Mice. ---
310  2019 Protective role of relaxin in a mouse model of aristolochic acid nephropathy. AAN, RLX
311  2019 Recognition of the toxicity of aristolochic acid. AAN, HCC
312  2019 Reply to HEP-19-1824. AAI, HCC
313  2019 The Disturbance of Hepatic and Serous Lipids in Aristolochic Acid Iota Induced Rats for Hepatotoxicity Using Lipidomics Approach. AAI, AAN
314  2019 The Impact of p53 on Aristolochic Acid I-Induced Gene Expression In Vivo. AAI, BW
315  2019 The impact of p53 on aristolochic acid I-induced nephrotoxicity and DNA damage in vivo and in vitro. BW, GC-MS, MEFs, NMR
316  2019 The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers. AAI, HCC, PTEN
317  2020 Aristolochic Acid-Induced Nephrotoxicity: Molecular Mechanisms and Potential Protective Approaches. UUC
318  2020 Effect of prednisolone on glyoxalase 1 in an inbred mouse model of aristolochic acid nephropathy using a proteomics method with fluorogenic derivatization-liquid chromatography-tandem mass spectrometry. GLO1, TPI
319  2020 Hirsutella sinensis inhibits NLRP3 inflammasome activation to block aristolochic acid-induced renal tubular epithelial cell transdifferentiation. AAN, HS
320  2020 Integrative genomic study of Chinese clear cell renal cell carcinoma reveals features associated with thrombus. ccRCC, ccRCC-TT
321  2020 Upregulation of miR-101a Suppresses Chronic Renal Fibrosis by Regulating KDM3A via Blockade of the YAP-TGF-beta-Smad Signaling Pathway. alpha-SMA, FISH, qRT-PCR, UUO